115 related articles for article (PubMed ID: 29234076)
1. Molecular mechanism of K65 acetylation-induced attenuation of Ubc9 and the NDSM interaction.
Naik MT; Kang M; Ho CC; Liao PH; Hsieh YL; Naik NM; Wang SH; Chang I; Shih HM; Huang TH
Sci Rep; 2017 Dec; 7(1):17391. PubMed ID: 29234076
[TBL] [Abstract][Full Text] [Related]
2. Ubc9 acetylation modulates distinct SUMO target modification and hypoxia response.
Hsieh YL; Kuo HY; Chang CC; Naik MT; Liao PH; Ho CC; Huang TC; Jeng JC; Hsu PH; Tsai MD; Huang TH; Shih HM
EMBO J; 2013 Mar; 32(6):791-804. PubMed ID: 23395904
[TBL] [Abstract][Full Text] [Related]
3. An extended consensus motif enhances the specificity of substrate modification by SUMO.
Yang SH; Galanis A; Witty J; Sharrocks AD
EMBO J; 2006 Nov; 25(21):5083-93. PubMed ID: 17036045
[TBL] [Abstract][Full Text] [Related]
4. Transcription regulation of nuclear receptor PXR: Role of SUMO-1 modification and NDSM in receptor function.
Priyanka ; Kotiya D; Rana M; Subbarao N; Puri N; Tyagi RK
Mol Cell Endocrinol; 2016 Jan; 420():194-207. PubMed ID: 26549688
[TBL] [Abstract][Full Text] [Related]
5. Author Correction: Molecular mechanism of K65 acetylation-induced attenuation of Ubc9 and the NDSM interaction.
Naik MT; Kang M; Ho CC; Liao PH; Hsieh YL; Naik NM; Wang SH; Chang I; Shih HM; Huang TH
Sci Rep; 2018 Mar; 8(1):5022. PubMed ID: 29555948
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for SUMO-E2 interaction revealed by a complex model using docking approach in combination with NMR data.
Ding H; Yang Y; Zhang J; Wu J; Liu H; Shi Y
Proteins; 2005 Dec; 61(4):1050-8. PubMed ID: 16224784
[TBL] [Abstract][Full Text] [Related]
7. Is Transthyretin a Regulator of Ubc9 SUMOylation?
Wieczorek E; Kędracka-Krok S; Sołtys K; Jankowska U; Hołubowicz R; Seliga J; Ożyhar A
PLoS One; 2016; 11(8):e0160536. PubMed ID: 27501389
[TBL] [Abstract][Full Text] [Related]
8. SUMO: getting it on.
Anckar J; Sistonen L
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1409-13. PubMed ID: 18031233
[TBL] [Abstract][Full Text] [Related]
9. Solution structure of human SUMO-3 C47S and its binding surface for Ubc9.
Ding H; Xu Y; Chen Q; Dai H; Tang Y; Wu J; Shi Y
Biochemistry; 2005 Mar; 44(8):2790-9. PubMed ID: 15723523
[TBL] [Abstract][Full Text] [Related]
10. Ubc9 sumoylation regulates SUMO target discrimination.
Knipscheer P; Flotho A; Klug H; Olsen JV; van Dijk WJ; Fish A; Johnson ES; Mann M; Sixma TK; Pichler A
Mol Cell; 2008 Aug; 31(3):371-82. PubMed ID: 18691969
[TBL] [Abstract][Full Text] [Related]
11. Identification of sumoylation inhibitors targeting a predicted pocket in Ubc9.
Kumar A; Ito A; Hirohama M; Yoshida M; Zhang KY
J Chem Inf Model; 2014 Oct; 54(10):2784-93. PubMed ID: 25191977
[TBL] [Abstract][Full Text] [Related]
12. Orthoreovirus outer-fiber proteins are substrates for SUMO-conjugating enzyme Ubc9.
Yu F; Wang H; Wang L; Lu L
Oncotarget; 2016 Nov; 7(48):79814-79827. PubMed ID: 27806335
[TBL] [Abstract][Full Text] [Related]
13. Unique binding interactions among Ubc9, SUMO and RanBP2 reveal a mechanism for SUMO paralog selection.
Tatham MH; Kim S; Jaffray E; Song J; Chen Y; Hay RT
Nat Struct Mol Biol; 2005 Jan; 12(1):67-74. PubMed ID: 15608651
[TBL] [Abstract][Full Text] [Related]
14. Role of the CBP catalytic core in intramolecular SUMOylation and control of histone H3 acetylation.
Park S; Stanfield RL; Martinez-Yamout MA; Dyson HJ; Wilson IA; Wright PE
Proc Natl Acad Sci U S A; 2017 Jul; 114(27):E5335-E5342. PubMed ID: 28630323
[TBL] [Abstract][Full Text] [Related]
15. Both conditional ablation and overexpression of E2 SUMO-conjugating enzyme (UBC9) in mouse pancreatic beta cells result in impaired beta cell function.
He X; Lai Q; Chen C; Li N; Sun F; Huang W; Zhang S; Yu Q; Yang P; Xiong F; Chen Z; Gong Q; Ren B; Weng J; Eizirik DL; Zhou Z; Wang CY
Diabetologia; 2018 Apr; 61(4):881-895. PubMed ID: 29299635
[TBL] [Abstract][Full Text] [Related]
16. Protein interactions in the sumoylation cascade: lessons from X-ray structures.
Tang Z; Hecker CM; Scheschonka A; Betz H
FEBS J; 2008 Jun; 275(12):3003-15. PubMed ID: 18492068
[TBL] [Abstract][Full Text] [Related]
17. Targeting the SUMO E2 conjugating enzyme Ubc9 interaction for anti-cancer drug design.
Duan X; Trent JO; Ye H
Anticancer Agents Med Chem; 2009 Jan; 9(1):51-4. PubMed ID: 19149481
[TBL] [Abstract][Full Text] [Related]
18. Ubc9 sumoylation controls SUMO chain formation and meiotic synapsis in Saccharomyces cerevisiae.
Klug H; Xaver M; Chaugule VK; Koidl S; Mittler G; Klein F; Pichler A
Mol Cell; 2013 Jun; 50(5):625-36. PubMed ID: 23644018
[TBL] [Abstract][Full Text] [Related]
19. Role of an N-terminal site of Ubc9 in SUMO-1, -2, and -3 binding and conjugation.
Tatham MH; Kim S; Yu B; Jaffray E; Song J; Zheng J; Rodriguez MS; Hay RT; Chen Y
Biochemistry; 2003 Aug; 42(33):9959-69. PubMed ID: 12924945
[TBL] [Abstract][Full Text] [Related]
20. Novel proteomics strategy brings insight into the prevalence of SUMO-2 target sites.
Blomster HA; Hietakangas V; Wu J; Kouvonen P; Hautaniemi S; Sistonen L
Mol Cell Proteomics; 2009 Jun; 8(6):1382-90. PubMed ID: 19240082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
